Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 149.69M | 144.28M | 127.04M | 107.67M | 86.35M | 88.64M |
Gross Profit | 111.69M | 105.64M | 61.94M | 52.80M | 40.33M | 52.45M |
EBITDA | 6.92M | -5.06M | -103.79M | -176.66M | -215.25M | -222.53M |
Net Income | -931.00K | -13.58M | -110.56M | -182.02M | -220.68M | -227.28M |
Balance Sheet | ||||||
Total Assets | 232.09M | 233.15M | 222.51M | 250.95M | 305.71M | 353.56M |
Cash, Cash Equivalents and Short-Term Investments | 40.63M | 59.28M | 80.41M | 84.85M | 157.58M | 208.49M |
Total Debt | 176.74M | 177.76M | 179.63M | 157.48M | 159.50M | 24.61M |
Total Liabilities | 259.35M | 266.80M | 256.48M | 237.38M | 228.14M | 117.06M |
Stockholders Equity | -27.26M | -33.65M | -33.97M | 13.57M | 77.57M | 236.49M |
Cash Flow | ||||||
Free Cash Flow | -29.53M | -24.23M | -60.33M | -148.74M | -206.38M | -191.63M |
Operating Cash Flow | -28.15M | -22.53M | -58.79M | -146.91M | -203.35M | -184.82M |
Investing Cash Flow | 25.00M | 18.71M | 18.00M | -3.32M | 32.73M | 208.96M |
Financing Cash Flow | 1.28M | 940.00K | 54.11M | 75.06M | 156.03M | 9.11M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | $7.91B | -0.36 | -41.71% | 2.23% | 23.45% | -1.86% | |
48 Neutral | $202.35M | ― | 40.36% | ― | 9.78% | 98.13% | |
47 Neutral | $361.60M | ― | -48.57% | ― | -100.00% | 83.98% | |
47 Neutral | $321.67M | ― | -569.99% | ― | 33.39% | -7.11% | |
44 Neutral | $228.17M | ― | -37.89% | ― | -100.00% | -62.44% | |
35 Underperform | $455.32M | ― | -140.33% | ― | ― | -0.69% | |
33 Underperform | $281.79M | ― | -89.37% | ― | ― | 9.84% |
Heron Therapeutics, Inc. has entered into a new office lease agreement for its corporate headquarters in Cary, North Carolina, effective August 22, 2025. The lease spans approximately 111 months with an option to extend and includes a right of first refusal for additional space, indicating a strategic move to accommodate future growth and operational needs.
On August 13, 2025, Heron Therapeutics‘ Board of Directors adopted a Tax Benefit Preservation Plan to protect the company’s net operating loss carryforwards (NOLs), valued at approximately $1.37 billion as of December 31, 2024. The plan, effective August 14, 2025, aims to deter any single investor or group from acquiring 4.99% or more of Heron’s outstanding common stock, which could trigger an ‘ownership change’ under Section 382 of the Internal Revenue Code and limit the company’s ability to use its NOLs to offset future taxable income. This strategic move is intended to enhance Heron’s financial position and support its growth strategy.
On August 8, 2025, Heron Therapeutics entered into a Cooperation Agreement with Rubric Capital Management, which involves changes to the company’s Board of Directors, including the appointment of a new director nominated by Rubric. Additionally, Heron Therapeutics has undertaken significant refinancing transactions, including amendments to its working capital facility and the issuance of convertible senior unsecured promissory notes, which closed on August 12, 2025. These strategic moves are expected to strengthen the company’s financial position and support its ongoing operations.
On August 6, 2025, Heron Therapeutics entered into a Framework Agreement with Patheon Austria GmbH & Co KG and Thermo Fisher Scientific Inc. This agreement outlines the terms for Patheon to manufacture and supply specific quantities of products to Heron Therapeutics, with a commitment to purchase 38,400 kg of products by December 31, 2026. The agreement also includes ongoing stability studies and warehousing services, while terminating certain previous agreements between the parties.
On August 8, 2025, Heron Therapeutics announced several financial and strategic initiatives aimed at enhancing its financial flexibility and supporting growth. The company entered into a secured debt transaction to increase its loan capacity to $150 million and extend debt maturities to 2030. Additionally, Heron executed a convertible note exchange and issuance, alongside a private placement expected to raise $27.7 million, all set to close on August 12, 2025. These moves are part of a comprehensive capital restructuring effort that has already reduced total debt from $175 million to $145 million. Heron’s Q2 2025 financial results showed a net revenue of $37.2 million, with significant growth in its acute care franchise, particularly for ZYNRELEF and APONVIE, reflecting strong commercial execution and expanding market adoption.
On June 12, 2025, Heron Therapeutics held its Annual Meeting of Stockholders where key decisions were made, including the election of six directors and the ratification of Withum Smith+Brown, PC as the independent accounting firm for 2025. Stockholders also approved executive compensation for 2024 and decided to conduct annual advisory votes on executive pay, aligning with the company’s recommendations. These decisions reflect the company’s commitment to governance and transparency, potentially impacting its stakeholder relationships positively.